Blog Posts

Parkinson-like neurotoxicity in female patients treated with Ide-cel

Photo from Samer Al Hadidi/X

Jul 30, 2024, 12:38

Parkinson-like neurotoxicity in female patients treated with Ide-cel

Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, shared a post on X, about a recent paper titled ”Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel” published in HemaSphere.

Authors: Audrey Couturier, Martine Escoffre, Frédérique Leh, Anne-Sophie Villoteau, Xavier Palard, Florence Le Jeune, Olivier Decaux, Thierry Lamy, Roch Houot.

Samer Al Hadidi

”Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel.

Nice summary tables of reported Parkinson-like neurotoxicity with BCMA CAR-T.

Such rare AEs occur with idecabtagene-vicleucel as well asciltacabtagene autoleucel – important for informed consent.”

Samer Al Hadidi

Source: Samer Al Hadidi/X

Anne-Sophie Villoteau asciltacabtagene autoleucel Audrey Couturier cancer cancer treatment Florence Le Jeune Frédérique Leh HemaSphere idecabtagene vicleucel Martine Escoffre Olivier Decaux OncoDaily Oncology Roch Houot Samer Al Hadidi Thierry Lamy UAMS Myeloma Center Xavier Palard

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC